Eagle Pharmaceuticals Inc (EGRX) — Cash Flow-to-Debt Ratio
Eagle Pharmaceuticals Inc (EGRX) has a Cash Flow-to-Debt Ratio of 0.00x as of June 2023, meaning its operating cash flow of $-126.00K could theoretically repay 0% of its total liabilities ($152.78 Million) in one year. See EGRX free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Eagle Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2022)
Historical debt coverage capacity for Eagle Pharmaceuticals Inc across 11 annual periods. Also explore Eagle Pharmaceuticals Inc (EGRX) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Eagle Pharmaceuticals Inc (2012–2022)
Year-by-year debt coverage analysis for Eagle Pharmaceuticals Inc. For market capitalisation and broader financial context, see Eagle Pharmaceuticals Inc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2022 | 0.18x | $30.80 Million | $172.60 Million | ▼ -51.1% |
| 2021 | 0.37x | $28.22 Million | $77.28 Million | ▼ -50.4% |
| 2020 | 0.74x | $49.50 Million | $67.18 Million | ▼ -0.8% |
| 2019 | 0.74x | $55.99 Million | $75.38 Million | ▲ +10.4% |
| 2018 | 0.67x | $52.38 Million | $77.84 Million | ▲ +3.8% |
| 2017 | 0.65x | $58.92 Million | $90.92 Million | ▼ -24.1% |
| 2016 | 0.85x | $53.21 Million | $62.34 Million | ▲ +400.9% |
| 2015 | -0.28x | $-9.72 Million | $34.26 Million | ▲ +58.4% |
| 2014 | -0.68x | $-13.84 Million | $20.32 Million | ▼ -86.0% |
| 2013 | -0.37x | $-5.88 Million | $16.05 Million | ▲ +49.3% |
| 2012 | -0.72x | $-15.55 Million | $21.54 Million | — |